基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响

汤柳星; 吕波; 蒋文婷; 项铮; 沈珠; 潘杰; 苏存锦

doi:10.6039/j.issn.1001-0408.2024.06.17

您当前的位置：

首页 >

文章列表页 >

基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响

药物与临床 | 更新时间：2024-04-09

- 基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响
- Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in stage Ⅲ and Ⅳ colorectal cancer
- 中国药房 2024年35卷第6期页码：734-738
- 作者机构：
  
  苏州大学附属第二医院药学部，江苏苏州　215004
- 作者简介：
  
  主管药师。研究方向：临床药学和个体化给药。 E-mail：gaodadexing@163.com
  副主任药师，博士。研究方向：神经药理学。E-mail：sucjgh@vip.163.com
- 基金信息：
  
  苏州市科技发展计划项目(SKYXD2022023;SYSD2020185);苏州市姑苏卫生人才计划(GSWS2021022);苏大附二院科研预研基金项目(SDFEYBS2015)
- DOI：10.6039/j.issn.1001-0408.2024.06.17
  中图分类号： R979.1
- 纸质出版日期：2024-03-30，
  
  收稿日期：2023-09-19，
  
  修回日期：2024-02-28，
扫描看全文
汤柳星,吕波,蒋文婷等.基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响 ^Δ[J].中国药房,2024,35(06):734-738.

TANG Liuxing,LYU Bo,JIANG Wenting,et al.Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in stage Ⅲ and Ⅳ colorectal cancer[J].ZHONGGUO YAOFANG,2024,35(06):734-738.
汤柳星,吕波,蒋文婷等.基因多态性对含奥沙利铂化疗方案治疗Ⅲ、Ⅳ期结直肠癌疗效及毒副作用的影响 ^Δ[J].中国药房,2024,35(06):734-738. DOI： 10.6039/j.issn.1001-0408.2024.06.17.

TANG Liuxing,LYU Bo,JIANG Wenting,et al.Effects of gene polymorphism on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in stage Ⅲ and Ⅳ colorectal cancer[J].ZHONGGUO YAOFANG,2024,35(06):734-738. DOI： 10.6039/j.issn.1001-0408.2024.06.17.

摘要

目的

探讨

GSTP1、XRCC1、ABCB1、MTHFR

基因多态性对接受含奥沙利铂化疗方案Ⅲ、Ⅳ期结直肠癌患者疗效及毒副作用的影响。

方法

回顾性收集2018年9月至2020年3月苏州大学附属第二医院接受含奥沙利铂化疗方案（XELOX、FOLFOX）的Ⅲ、Ⅳ期结直肠癌患者资料76例。采用单因素、多因素COX回归模型分析基因型与无进展生存期（PFS）、毒副作用的相关性。

结果

ABCB1

3435T＞C位点C等位基因（TC/CC型）携带者的疾病进展风险显著高于TT基因型患者[HR＝2.39，95%CI（1.05，5.50），

＝0.038]，Ⅳ期患者的疾病进展风险显著高于Ⅲ期患者[HR＝8.11，95%CI（3.39，19.40），

＜0.001]；化疗方案、Karnofsky功能状态评分、肿瘤部位对疾病进展的影响不明显（

＞0.05）。基因位点的突变与不良反应无相关性（

＞0.05）。

结论

携带

ABCB1

TC/CC型且接受含奥沙利铂化疗方案患者的疾病进展风险较高，这可能与接受此类化疗方案的Ⅳ期结直肠癌患者（TT型）有更长的PFS相关，而

GSTP1、XRCC1、MTHFR

基因多态性无显著影响。

Abstract

OBJECTIVE

To investigate the effects of

GSTP1， XRCC1， ABCB1， MTHFR

gene polymorphisms on efficacy and toxic effect of chemotherapy regimen containing oxaliplatin in patients with stage Ⅲ and Ⅳ colorectal cancer patients.

METHODS

Clinical data of 76 patients with stage Ⅲ and Ⅳ colorectal cancer who received chemotherapy regimen containing oxaliplatin （XELOX，FOLFOX） were collected from the Second Affiliated Hospital of Soochow University from September 2018 to March 2020. The correlation of genotypes with progression-free survival （PFS） and toxic effect was analyzed by using univariate and multivariate COX regression model.

RESULTS

Carriers of the

ABCB1

3435T＞C locus C allele （TC/CC） had a significantly higher risk of progression compared to TT genotype patients [HR＝2.39， 95%CI （1.05，5.50），

＝0.038]. The risk of progression in patients at stage Ⅳ was significantly higher than those at stage Ⅲ [HR＝8.11， 95%CI（3.39，19.40），

＜0.001]. Chemotherapy regimen， Karnofsky performance status score and tumor site had no significant effect on disease progression （

＞0.05）. Mutations in gene loci were not correlated with adverse reactions （

＞0.05）.

CONCLUSIONS

Patients carrying

ABCB1

TC/CC and receiving chemotherapy regimen containing oxaliplatin have a higher risk of disease progression， which may be associated with longer PFS in patients （TT genotype） with stage Ⅳ colorectal cancer receiving the chemotherapy， while

GSTP1

，

XRCC1

， and

MTHFR

gene polymorphisms have no significant impact.

关键词

奥沙利铂基因多态性结直肠癌疗效毒副作用相关性

Keywords

gene polymorphismcolorectal cancerefficacytoxic effectcorrelation

references

SUNG H，FERLAY J，SIEGEL RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

WU H Z，KANG H，LIU Y，et al. Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis[J]. Pharmacogenomics，2013，14（8）：897-911.

MCLEOD H L，SARGENT D J，MARSH S，et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer：results from North American Gastrointestinal Intergroup Trial N9741[J]. J Clin Oncol，2010，28（20）：3227-3233.

NAHID N A，APU M N H，ISLAM M R，et al. DPYD*2A and MTHFR C677T predict toxicity and efficacy，respectively，in patients on chemotherapy with 5-fluorouracil for colorectal cancer[J]. Cancer Chemother Pharmacol，2018，81（1）：119-129.

AFIFAH N N，DIANTINI A，INTANIA R，et al. Genetic polymorphisms and the efficacy of platinum-based chemotherapy：review[J]. Pharmgenomics Pers Med，2020，13：427-444.

ARNOULD S，HENNEBELLE I，CANAL P，et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines[J]. Eur J Cancer，2003，39（1）：112-119.

SALTZ L B，CLARKE S，DÍAZ-RUBIO E，et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer：a randomized phase Ⅲ study[J]. J Clin Oncol，2023，41（21）：3663-3669.

CECCHIN E，D’ANDREA M，LONARDI S，et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin（FOLFOX4）regimen[J]. Pharmacogenomics J，2013，13（5）：403-409.

HUANG M Y，HUANG M L，CHEN M J，et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy[J]. Pharmacogenet Genomics，2011，21（1）：18-25.

THEILE D，GREBHARDT S，HAEFELI W E，et al. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy[J]. Biochem Pharmacol，2009，78（11）：1366-1373.

EVANS W E，MCLEOD H L. Pharmacogenomics：drug disposition，drug targets，and side effects[J]. N Engl J Med，2003，348（6）：538-549.

YUE A M，XIE Z B，ZHAO H F，et al. Associations of ABCB1 and XPC genetic polymorphisms with susceptibi-lity to colorectal cancer and therapeutic prognosis in a Chinese population[J]. Asian Pac J Cancer Prev，2013，14（5）：3085-3091.

TROIA B D，DALU D，FILIPAZZI V，et al. ABCB1 c.3435C＞T polymorphism is associated with platinum toxicity：a preliminary study[J]. Cancer Chemother Pharmacol，2019，83（4）：803-808.

李然，马旭，白羽，等. 奥沙利铂在消化道肿瘤患者中药物相关基因单核苷酸多态性及化疗不良反应相关性研究[J]. 中国医院药学杂志，2020，40（2）：203-207.

LI R，MA X，BAI Y，et al. Single nucleotide polymorphism of oxaliplatin related genes in digestive tract tumors and the correlation of oxaliplatin chemotherapy adverse reactions[J]. Chin J Hosp Pharm，2020，40（2）：203-207.

YE F H，LIU Z F，TAN A H，et al. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer：a meta-analysis[J]. Cancer Chemother Pharmacol，2013，71（3）：733-740.

WANG Z，CHEN J Q，LIU J L，et al. Polymorphisms in ERCC1，GSTs，TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy：a systematic review[J]. BMC Gastroenterol，2012，12：137.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

成人患者体内伏立康唑代谢的影响因素分析

我院2008－2012年抗菌药物使用量与革兰阴性菌耐药性分析

天津市各级医疗机构输液相关不良事件与滴注速度相关性分析

紫锥菊的形态学性状、分布高度与质量相关性研究Δ

头孢曲松致免疫性溶血的文献分析